When we talk about the 10 pharmaceutical scandals that have sent shockwaves through the medical world, the common thread is a relentless pursuit of profit that tramples ethics and, at times, the law. From inflated price tags to manipulated trial data, these ten cases expose how some of the biggest drug makers have bent—or outright broken—rules to line their coffers, often at the expense of patients and taxpayers alike.
10 Pharmaceutical Scandals Unveiled
10 Pfizer Celebrex Scandal
In 2012, Pfizer found itself at the centre of a controversy surrounding its arthritis medication Celebrex. A lawsuit revealed that company executives cherry‑picked safety data, presenting a distorted picture of the drug’s risk profile. While a year‑long study showed Celebrex posed no greater stomach risk than competing anti‑inflammatories, a six‑month snapshot suggested it was gentler on the gut. Pfizer’s researchers highlighted the short‑term findings to claim a safety advantage over drugs like ibuprofen, even though the longer data painted a different story.
Internal emails uncovered during the litigation demonstrated that senior scientists deliberately framed the data to make Celebrex appear more favourable. The drug, a major revenue driver for Pfizer, ultimately led the firm to settle an investor class‑action for over $164 million, though the company continued to deny any misconduct.
9 EpiPen Scandal
The life‑saving auto‑injector EpiPen, essential for treating severe allergic reactions, became a textbook example of price exploitation. Although it cost Mylan roughly $1 to produce a two‑pack, the company escalated the retail price from about $100 to more than $600 per pair, sparking outrage across the nation.
During its first five years of ownership, Mylan funneled nearly $8 million into lobbying efforts to mandate EpiPen availability in schools, eventually securing legislation that incentivised states to require the device. With government agencies now footing part of the bill, Mylan continued to hike the price until it breached the $600 threshold.
An investigation probed the steep increase, but Mylan defended the move by citing product enhancements. Ultimately, the firm agreed to a $465 million settlement to resolve claims that it had misclassified EpiPen as a generic drug to avoid paying Medicaid rebates.
8 Merck Vioxx Scandal
Vioxx, Merck’s once‑popular painkiller, was marketed as a breakthrough anti‑inflammatory medication. Early on, the drug seemed effective, but subsequent studies linked it to a heightened risk of strokes and heart attacks. These safety concerns prompted Merck to voluntarily withdraw Vioxx from the market.
Although the FDA approved Vioxx in 1999 based on data suggesting minimal cardiovascular risk, later investigations uncovered evidence of serious adverse events. Merck dismissed the emerging studies as flawed, and the regulator appeared slow to act, fueling speculation of a cover‑up between the company and the FDA. The fallout culminated in hefty fines and numerous lawsuits against Merck.
7 Rochester Drug Cooperatives Opioid Scandal
The opioid crisis, responsible for over 600,000 American deaths between 1999 and 2021, exposed the dark side of pharmaceutical distribution. Rochester Drug Cooperative (RDC), a wholesale distributor, became the first company formally accused of drug trafficking as part of the epidemic.
Authorities alleged that RDC shipped massive quantities of highly addictive opioids to pharmacies it knew were dispensing them illegally. The company eventually admitted to drug‑trafficking activities, filed for bankruptcy, and ceased operations.
RDC’s former CEO, Laurence Doud, received a 27‑month prison sentence after prosecutors argued he prioritized his paycheck over preventing opioids from reaching addicts. The case underscored how distributors can fuel public‑health disasters when profit eclipses responsibility.
6 Valeant Scandal
Valeant Pharmaceuticals earned widespread ire for its aggressive price‑inflation tactics. After acquiring drugs such as Isuprel, Isoprenaline, and Nitropress, the company dramatically hiked their prices—some soaring six‑fold—sparking a federal investigation into its pricing and distribution practices.
In 2016, former executives Gary Tanner and Andrew Davenport faced charges for operating kickback schemes and conspiring to use a shell company, Philidor, as a conduit for distributing Valeant’s products. Additionally, former CEO Michael Pearson was scrutinised for potential fraud earlier that year. The scandal painted a picture of a firm willing to exploit patients and insurers for profit.
5 Questcor Price Hike Scandal
Questcor Pharmaceuticals engineered one of the most egregious drug‑price spikes in U.S. history. Whistleblowers alleged the company bribed physicians to boost sales of its flagship product, H.P. Acthar Gel, a treatment for a rare infant seizure disorder. The medication’s price exploded from a $40 vial in 2000 to roughly $39,000 within a decade—a staggering 97,000 % increase.
The insiders revealed that Questcor not only lied to the FDA but also offered illicit incentives to doctors, driving sales skyward. The price surge generated over $1 billion in annual revenue, with Medicare accounting for about 25 % of sales. Medicare reimbursements ballooned from $50 million in 2011 to $725 million by 2018, effectively siphoning public funds.
4 Merck MMR Scandal
Merck’s MMR vaccine, designed to protect children against measles, mumps, and rubella, became embroiled in a long‑standing controversy. In 1999, the FDA discovered that the vaccine’s potency was deteriorating because the live virus was dying off while the product sat on shelves.
To compensate, Merck “overfilled” the vaccine by adding extra virus, hoping to preserve efficacy. Nevertheless, the virus continued to degrade, prompting the agency to issue two warning letters for failing to report potentially sub‑potent doses. Lab personnel later testified that management instructed them to falsify dates to mask the issue.
Whistleblowers filed a lawsuit alleging taxpayer fraud, but the case was dismissed before trial. While Merck denied wrongdoing, critics continue to question whether the compromised potency contributed to outbreaks among vaccinated populations.
3 Roche Fraud Scandal
Roche Pharmaceutical Group faced a massive compliance breach when European regulators uncovered that the company had failed to disclose thousands of serious side‑effects linked to 19 of its medicines. The European Commission initially projected fines of around $685 million for the omission.
After extensive inspections, Roche took swift corrective action, enhancing its medical‑compliance systems and addressing the deficiencies. Although the case was eventually closed, the episode raised concerns that undisclosed adverse events may have contributed to numerous illnesses and deaths.
2 Abilify Scandal
Bristol‑Myers Squibb and Otsuka Pharmaceutical jointly marketed Abilify, an antipsychotic used for conditions such as schizophrenia and bipolar disorder. A multi‑state investigation alleged that the companies promoted the drug for off‑label uses, especially targeting elderly patients with dementia.
Evidence showed that Otsuka’s medication guide warned of an increased risk of death in this vulnerable group. While Bristol‑Myers Squibb denied misconduct, it consented to marketing restraints and paid $19.5 million to settle the allegations that it had misled physicians about the drug’s dangers and pushed unapproved indications.
1 Pharma Bro Scandal
Martin Shkreli, infamously dubbed “Pharma Bro,” became the face of pharmaceutical profiteering when he, as CEO of Turing Pharmaceuticals, hiked the price of Daraprim—a treatment for a rare parasitic infection—from $13.50 per pill to about $750. The drug is vital for patients with AIDS, cancer, and pregnant women.
Shkreli defended the surge as a triumph of capitalism, igniting nationwide outrage. In 2015, he was arrested on securities‑fraud charges related to his hedge‑fund activities, resigned from Turing, and was later convicted, receiving a seven‑year prison sentence. He was also ordered to return $64.6 million in profits earned from the Daraprim price increase.